Clinical trial analytics · Clario
Clario
Clinical trial endpoint technology combining medical imaging, eCOA, cardiac safety, and wearable data collection.
Clario supplies endpoint data-collection and analysis services for clinical trials, spanning medical imaging (MRI, PET, SPECT), electronic clinical outcome assessment (eCOA), cardiac safety (ECG), precision motion sensors, and respiratory measurement. Rather than a general EDC, it specializes in capturing and centrally interpreting the specific endpoint data types trial protocols require, then feeding standardized results back into a sponsor's broader data management system such as Medidata or Veeva. Clario formed from the 2021 merger of eResearchTechnology (ERT) and Bioclinica, two established clinical-trial technology and imaging-core-lab businesses, and has since been owned by a group of investment firms. In late 2025 Thermo Fisher Scientific agreed to acquire Clario, a deal not yet closed as of this writing. Clario serves pharmaceutical sponsors and CROs running trials that depend on centrally read imaging or patient-reported outcome data, particularly in neuroscience, oncology, and cardiovascular studies.
At a glance
| Vendor | Clario |
|---|---|
| Pricing model | Quote only |
| Free tier | No |
| Deployment | Cloud |
| Open source | No |
| Best for | Sponsors running trials that need centrally read imaging, eCOA, or cardiac safety endpoints rather than general data capture. |
Pricing
Priced per study through direct negotiation with Clario; no public price list.
Pricing has not been verified yet — see the vendor's site.
Features
- Centralized medical imaging core lab (MRI, PET, SPECT)
- Electronic clinical outcome assessment (eCOA)
- Cardiac safety and ECG data collection
- Precision motion and wearable sensor endpoints
- Respiratory endpoint measurement
- Therapeutic-area-specific endpoint scientists
- Data integration back to sponsor EDC/CTMS systems
Profile last reviewed September 21, 2026